These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 19088324)
1. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Rivera E; Lee J; Davies A Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324 [TBL] [Abstract][Full Text] [Related]
2. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [TBL] [Abstract][Full Text] [Related]
3. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Steinberg M Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366 [TBL] [Abstract][Full Text] [Related]
4. Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Halterman PA Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221 [TBL] [Abstract][Full Text] [Related]
5. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer. Bhushan S; Walko CM Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018 [TBL] [Abstract][Full Text] [Related]
6. The epothilones: how pharmacology relates to clinical utility. Michaud LB Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389 [TBL] [Abstract][Full Text] [Related]
7. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Yardley DA Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502 [TBL] [Abstract][Full Text] [Related]
8. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting. Cigler T; Vahdat L Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037 [TBL] [Abstract][Full Text] [Related]
9. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Vahdat L Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531 [TBL] [Abstract][Full Text] [Related]
10. The epothilones: translating from the laboratory to the clinic. Lee JJ; Swain SM Clin Cancer Res; 2008 Mar; 14(6):1618-24. PubMed ID: 18347162 [TBL] [Abstract][Full Text] [Related]
11. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. Morris PG; Fornier MN Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]. Villanueva C; Dufresne A; Pivot X; Viel E Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905 [TBL] [Abstract][Full Text] [Related]
13. Advances in breast cancer treatment: the emerging role of ixabepilone. Frye DK Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882 [TBL] [Abstract][Full Text] [Related]
14. Ixabepilone, a new treatment option for metastatic breast cancer. Toppmeyer DL; Goodin S Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567 [TBL] [Abstract][Full Text] [Related]
15. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. Boehnke Michaud L J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553 [TBL] [Abstract][Full Text] [Related]
16. Ixabepilone: clinical role in metastatic breast cancer. Denduluri N; Swain S Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133 [TBL] [Abstract][Full Text] [Related]
17. Current perspectives of epothilones in breast cancer. Cardoso F; de Azambuja E; Lago LD Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426 [TBL] [Abstract][Full Text] [Related]
18. Clinical studies with epothilones for the treatment of metastatic breast cancer. Vahdat LT Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796 [TBL] [Abstract][Full Text] [Related]
19. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Rivera E Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449 [TBL] [Abstract][Full Text] [Related]
20. Epothilones in breast cancer: current status and future directions. Atzori F; Fornier M Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]